Zacks Investment Research downgraded shares of VERTEX PHARM (VRTX) from NEUTRAL to UNDERPERFORM on October 01, 2012, with a target price of $53.90.
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on VERTEX PHARM (VRTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment